Quanterix Corp
QTRX
View Detailed Chart
5.430USD
-0.150-2.69%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
211.08MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.69%
5 Days
+12.89%
1 Month
+7.95%
6 Months
-24.58%
Year to Date
-48.92%
1 Year
-64.95%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Hold
Current Rating
6.250
Target Price
+12.01%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.23% year-on-year.
Overvalued
The company’s latest PE is -2.98, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 36.46M shares, decreasing 26.22% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.53M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.
Ticker SymbolQTRX
CompanyQuanterix Corp
CEODr. Masoud Toloue, Ph.D.
Websitehttps://www.quanterix.com/
Related Instruments
-0.32%
+0.66%
-0.41%
-1.01%
-0.46%
-0.19%
-0.04%
-1.02%
+1.23%
-0.64%
-1.80%
-0.27%
-2.84%
-1.19%
-0.78%
-0.30%
+0.98%
-0.72%
-1.25%
-3.23%
